For instance, the use of mut-KRAS patient-derived organoids and xenografts would represent an invaluable preclinical model to test novel proteasome inhibitors already in clinical trials for multiple myeloma, such as ONX 0914, carfilzomib, ixazomib and oprozomib. Here, KRAS is linked to AL amyloidosis.